crypto currency t Top Top stories

Russian Foreign Ministry Spokesperson Zacharova: The Russian Federation keeps in touch with all political forces in Syria. The Russian Federation is holding an operational headquarters meeting to discuss the security of Russians and Russian facilities in Syria.ZTE and ZTE Xinyun jointly released a digital intelligence financial solution. Recently, ZTE and ZTE Xinyun Cloud Service Co., Ltd. (referred to as "ZTE Xinyun") jointly released a digital intelligence financial solution based on digital nebula. The solution provides one-stop financial cloud application, fully supports financial functions and financial processes, solves breakpoints and pain points in the interaction between industry and finance, breaks the "data island" between systems, realizes the intelligent and efficient collection of business data and financial processing, and empowers the intelligent transformation of enterprise financial data.Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)

Eight-day four-board three-dimensional communication: the company's operation is normal, and the internal and external operating environment has not changed significantly. On December 9, December 10 and December 11, 2024, the company's closing price increase deviated by more than 20% for three consecutive trading days, which belongs to the abnormal fluctuation of stock trading. The company's operation is normal, and the internal and external operating environment has not changed significantly. The Company has no other circumstances that violate the provisions on fair disclosure of information.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Details of the "Teze Meeting" exposed Trump's friendliness. Zelensky said that he wanted security. Two sources said that during his first meeting with Trump after the US election, Ukrainian President Zelensky emphasized that Ukraine needed security in any negotiations with Russia to end the conflict. French President Macron presided over the meeting in Paris. The three leaders talked for 35 minutes without a consultant, and did not discuss any specific details of the vision of peace, but four people familiar with the matter said that Trump reiterated his hope for an immediate ceasefire and a rapid end to the war through negotiations. One of the sources said that Trump was friendly, respectful and open, and seemed to be listening. A source said: "Some key points were mentioned during the meeting. For example, some people said that peace needs to be guaranteed, because a ceasefire alone is not enough. Putin may break the ceasefire again without proper guarantee as before." The source said that Trump "he is considering all the details." Several officials close to Trump said that Trump's direct contacts with Zelensky were generally cordial, which was different from some of his previous public statements, including calling Zelensky "the greatest salesman on earth" because he requested and accepted billions of dollars in US military assistance.

Li Ziyuan: There are no matters that should be disclosed but not disclosed. Li Ziyuan issued a change announcement. After the company's self-inspection, the company's current production and operation activities are normal, there is no major adjustment in the market environment or industry policies, and the internal production and operation order is normal; , the company and the controlling shareholder and actual controller of the company have no matters that should be disclosed but not disclosed.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.